Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

EXACT SCIENCES CORP Regulatory Filings 2020

Oct 30, 2020

30597_rns_2020-10-30_612f3ce7-ba7c-4ee6-9e3d-bf91b539834a.zip

Regulatory Filings

Open in viewer

Opens in your device viewer

Field: Rule-Page

Field: /Rule-Page

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 27, 2020

EXACT SCIENCES CORPORATION

(Exact Name of Registrant as Specified in Charter)

Delaware 001-35092 02-0478229
(State or Other Jurisdiction of Incorporation) (Commission File Number) (I.R.S. Employer Identification No.)

5505 Endeavor Lane

Madison , WI 53719

(Address of Principal Executive Offices)(Zip Code)

Registrant’s telephone number, including area code: ( 608 ) 284-5700

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | | --- | --- | --- | | Common Stock, $0.01 par value per share | EXAS | The Nasdaq Stock Market LLC |

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Field: Rule-Page

Field: /Rule-Page

Field: Page; Sequence: 1

Field: /Page

3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

On October 23, 2020, as previously disclosed in its Quarterly Report on Form 10-Q for the period ended September 30, 2020 filed on October 27, 2020 (the “Form 10-Q”), Exact Sciences Corporation, a Delaware corporation (the “Company”), sent a notice (the “Notice”) to The Nasdaq Stock Market (“Nasdaq”) to notify Nasdaq of the Company’s inadvertent noncompliance with Nasdaq Listing Rule 5605(c)(2)(A) (the “Rule”), which prohibits members of a listed company’s audit committee from receiving, directly or indirectly, consulting fees of any amount. As described in Item 5 of Part II of the Form 10-Q, for the reasons described therein the Company was out of compliance with the Rule from July 25, 2019 to October 22, 2020.

By letter dated October 27, 2020 from Nasdaq’s Listing Qualifications department (the “Letter”), Nasdaq notified the Company that based on the facts disclosed to Nasdaq in the Notice and described in the Form 10-Q, Nasdaq had determined that the Company was in violation of the Rule from July 25, 2019 to October 22, 2020, that the Company had regained compliance with the Rule effective October 22, 2020, and that subject to reporting receipt of the Letter herein the matter was now closed.

Field: Page; Sequence: 2; Options: NewSection; Value: 2

Field: Sequence; Type: Arabic; Name: PageNo 2 Field: /Sequence

Field: /Page

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

/s/ Jeffrey T. Elliott
Jeffrey T. Elliott
Chief Financial Officer

Field: Page; Sequence: 3; Options: Last

Field: Sequence; Type: Arabic; Name: PageNo 3 Field: /Sequence

Field: /Page